Latest news and press releases about GeoVax Labs, Inc. (GOVX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform.
Price
| Price | $0.41 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.05 |
| EV / EBITDA | -0.09 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -561.15% |
| Return on Invested Capital | -463.53% |
| Return on Assets | -338.46% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAP · ADTX · AIMD · ANL · APLM · BLRX · ICU
Explore sector: Healthcare · Biotechnology
More sections of GOVX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks